Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Hypertension Highlights

Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function

Ingrid Fleming, Rudi Busse
Download PDF
https://doi.org/10.1161/01.HYP.0000208597.87957.89
Hypertension. 2006;47:629-633
Originally published March 23, 2006
Ingrid Fleming
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudi Busse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • EETs and Endothelium-Derived Hyperpolarizing Factor
    • More Than Regulators of Vascular Tone?
    • EETs and Hypertension
    • Acknowledgments
    • References
  • Info & Metrics
  • eLetters
Loading

Abstract

Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases. The activation of CYP epoxygenases in endothelial cells is an important step in the NO and prostacyclin-independent vasodilatation of several vascular beds, and EETs have been identified as an endothelium-derived hyperpolarizing factor. However, EETs also exert membrane potential-independent effects and modulate several signaling cascades that affect endothelial cell proliferation and angiogenesis. This review summarizes the role of CYP-derived EETs in endothelium-derived hyperpolarizing factor–mediated responses and highlights the evidence indicating that EETs are important second messengers involved in endothelial cell signaling pathways related to angiogenesis.

  • calcium channels
  • endothelium-derived factors
  • hypertension
  • vasodilatation

There is now considerable evidence linking the metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes with the regulation of vascular homeostasis and tone, as well as renal function. The enzymes in question fall into 2 classes: (1) the epoxygenases, which generate epoxyeicosatrienoic acids (EETs); and (2) the ω/ω-1 hydroxylases, which generate 20-hydroxyeicosatetraenoic acid (20-HETE).

EETs and Endothelium-Derived Hyperpolarizing Factor

Interest in the vascular actions of EETs was initially related to their identification as an endothelium-derived hyperpolarizing factor (EDHF), that is, compounds responsible for the NO and prostacyclin-independent but endothelium-dependent vasodilatation of some vascular beds. There is now convincing evidence indicating that the hyperpolarizing factor produced by coronary and renal arteries from several species (humans, pigs, cows, dogs, rats, and rabbits) displays characteristics similar to those of a cytochrome CYP-derived metabolite of arachidonic acid.1 A CYP-dependent, EDHF response has also been described in other human arteries/vascular beds including the mammary artery,2 the forearm vasculature,3 and thigh skeletal muscle circulation.4 However, the EDHF-mediated relaxations in human mesenteric arteries5 and renal arteries6 appear to be independent of CYP activity.

For those following the “EDHF story,” the literature has been highly confusing, and for several years the field seemed caught in a pantomime of “it is” versus “it isn’t” reports. One reason for the confusion was that although some EDHF-mediated responses could be attributed to a CYP-derived metabolite of arachidonic acid, there were clearly other responses that occurred entirely independently of the activation of a CYP enzyme. For comprehensive reviews on the nature of the different EDHFs, the reader should consult references.7–9

Part of the reason for some of the controversy was that EETs were initially reported to initiate smooth muscle hyperpolarization by activating iberiotoxin-sensitive large conductance Ca2+-activated K+ (BKCa) channels,10 whereas EDHF-dependent relaxation was more universally sensitive to the combination of charybdotoxin and apamin (inhibitors of small and intermediate conductance KCa channels) than to iberiotoxin.11 Another point that argued against the involvement of EETs in the regulation of vascular tone was that, whereas several of the initial studies aimed at characterizing EDHF used BKCa-expressing cultured smooth muscle cells as a detector, smooth muscle cells from many freshly isolated arteries do not express BKCa channels.12 It is now clear, however, that the decisive charybdotoxin and apamin-sensitive hyperpolarizing event in EDHF-mediated responses is the hyperpolarization of the vascular endothelium and not of smooth muscle cells.7 This realization has forced a reevaluation of the role of CYP products in EDHF-mediated responses.

In line with the definition of an EDHF, EETs were initially assumed to be generated by the vascular endothelium then to leave these cells and travel across the basal lamina to activate BKCa channels on the underlying vascular smooth muscle. This can undoubtedly occur when large amounts of EETs are generated, and EETs can be detected in the perfusate of isolated arteries after exposure to fluid shear stress13 or to agonist stimulation.14 Moreover, a recently developed EET-selective antagonist, 14,15-epoxyeicosa-5(Z)-monoenoic acid, is able to prevent the endothelium-dependent but NO- and prostacyclin-independent relaxation of bovine coronary arteries in an elegant bioassay model.15

EETs are not all metabolized via the same pathway, and although 5,6-EET is a preferred substrate for cyclooxygenase,16 8,9-, 11,12- and 14,15-EET are metabolized to the corresponding dihydroxy derivatives (the dihydroxyeicosatrienoic acids) by the soluble epoxide hydrolase (sEH),17 as well as by β-oxidation.18 This difference accounts for the finding that relaxation of the bovine coronary artery induced by a novel stable agonist of 5,6-EET, 5-(pentadeca-3(Z),6(Z),9(Z)-trienyloxy) pentanoic acid was inhibited by the cyclooxygenase inhibitor indomethacin.19 The recent development of sEH inhibitors has helped to determine the physiological consequences of enhanced CYP activity and EET formation. Inhibitors of this enzyme enhance iberiotoxin-sensitive, EET-induced vasodilator responses in isolated human coronary arterioles,20 highlighting the potential relevance of this pathway in humans. The latter observation is, however, controversial, and the bradykinin-induced relaxation of human small coronary arteries (diameter ≈300 μm) has also been recently described as depending on the activation of guanylyl cyclase, inwardly rectifying K+ channels, and the Na+-K+ ATPase by NO, as well as on the activation of small and intermediate conductance KCa channels by a factor that is not a CYP epoxygenase product or H2O2.21 Given the latter observations together with the consideration that EETs are rapidly metabolized by the sEH and the fact that the CYP-dependent EDHF-mediated relaxation of porcine coronary arteries is also sensitive to the combination of charybdotoxin and apamin, it seemed that EETs may exert additional functions within endothelial cells that ultimately result in the activation of small and intermediate conductance KCa channels.

The effects of EETs on small and intermediate conductance KCa channels need not be direct, and there is evidence indicating that endogenously generated EETs can activate KCa channels by activating membrane-associated second messengers.22 For example, EETs activate KCa channels in coronary smooth muscle cells via a Gαs-mediated mechanism23 and may alter the sensitivity of these channels to Ca2+.24 Moreover, the activation of protein kinase A (PKA) by 11,12-EET is implicated in afferent arteriole vasodilatation,25 and there is evidence suggesting that KCa channels are modulated by cAMP and PKA.26 EETs also play a key role in modulating intracellular Ca2+ levels in endothelial cells, as well as the endothelial cell hyperpolarization that occurs as a consequence of the activation of low and intermediate conductance KCa channels.27 This implies that CYP-derived EETs are basically intracellular amplifiers of the endothelial hyperpolarization response and goes a long way to explaining why EDHF appears to have different properties in different vessels. One potential mechanism underlying the EET-dependent potentiation of endothelial cell hyperpolarization involves the activation of nonselective cation channels of the transient receptor potential (Trp) family. Some of these channels possess an arachidonic acid binding site and can be activated by EETs.28 Indeed, it has been shown recently that the induction of CYP expression with nifedipine increases TrpV4 activity as do sEH inhibitors, which increase the intracellular EET concentration, and that the arachidonic acid–induced activation of TrpV4 can be attributed to a CYP-dependent process.29 Although we speculated that EETs may indirectly modulate the open probability of Trp channels via cAMP/PKA,27 a recent report suggests that TRPV4 forms a novel Ca2+ signaling complex with ryanodine receptors and BKCa channels that elicits smooth muscle hyperpolarization and arterial dilation via Ca2+-induced Ca2+ release.30

More Than Regulators of Vascular Tone?

Because the EETs are known to exert cellular effects that cannot necessarily be linked to the activation of KCa channels, it follows that the CYP-derived metabolites of arachidonic acid may be more than vasodilators/vasoconstrictors. Paracrine and autocrine effects of CYP metabolites have been described in endothelial and smooth muscle cells, but the intracellular second messenger role of EETs (and 20-HETE) may eventually turn out to be the most important function of these arachidonic acid derivatives. EETs, in particular 11,12- and 14,15-EET, activate several intracellular signaling molecules including PKA,25 tyrosine kinases and phosphatases,31,32 the p38 mitogen-activated protein (MAP) kinase,32 extracellular regulated protein kinases 1 and 2, and MAP kinase phosphatases at the same time as inhibiting the c-Jun N-terminal kinase.33

Of particular interest are reports that EETs affect endothelial cell proliferation and angiogenesis.34–37 Detailed analysis of the mechanisms involved indicate that EETs can transactivate the epidermal growth factor receptor38,39 and interact with fibroblast growth factor-2.40 The EET-mediated activation of the epidermal growth factor receptor leads, in turn, to the activation of the kinase Akt and an enhanced expression of cyclin D1. All 4 of the EET regioisomers have been reported to elicit an increase in Akt phosphorylation and cell proliferation in murine endothelial cells, but only the proliferative effects of 5,6- and 14,15-EET are reportedly sensitive to a phosphatidylinositol 3-kinase inhibitor, whereas the 8,9- and 11,12-EET–induced increase in [3H]thymidine incorporation seems to be dependent on the activation of the p38 MAP kinase.41 In contrast, in bovine aortic endothelial cells, 8,9-, 11,12-, and 14,15-EET–induced cell proliferation can be attenuated by MAP kinase kinase (MEK) and phosphatidylinositol 3-kinase inhibition.42 Other signaling pathways also contribute to the increase in cyclin D1 expression, including the MAP kinase phosphatase-1, which decreases c-Jun N-terminal kinase activity.33 Activation of Akt by EETs also induces the phosphorylation and, therefore, inhibition of the forkhead factors FOXO1 and FOXO3a and subsequently a decrease in the expression of the cyclin-dependent kinase inhibitor p27kip1.43 The involvement of this mechanism in the CYP 2C9–induced endothelial cell proliferation could be demonstrated by the transfection of CYP 2C9–overexpressing cells with either a dominant-negative Akt or a constitutively active FOXO3a, which both inhibit CYP 2C9–induced endothelial cell proliferation.43

EETs and Hypertension

Because EETs play a role in the regulation of vascular tone, it follows that their altered generation and/or degradation may contribute to the development of some forms of hypertension. The relationship between CYP epoxygenase expression/ activity and hypertension is, however, not always straightforward, and although it would seem logical to look for a link between decreased CYP epoxygenase expression and hypertension, a number of experimental findings have suggested that quite the opposite is the case. There is evidence suggesting that CYP expression44–46 and EET generation are increased in hypertension,47,48 during salt loading,49 as well as in hypercholesterolemia.50 Certainly, the cyclooxygenase-independent renal vasodilatation produced by arachidonic acid is enhanced rather than blunted in spontaneously hypertensive rats (SHRs) at high-perfusion pressures.48 The latter response could be characterized pharmacologically as being related to the production of an EET, and 5,6-EET, 8,9-EET, and 11,12-EET all induced renal vasodilatation (5,6-EET was the most potent renal vasodilator), whereas 14,15-EET produced vasoconstriction.51 However, there are also reports linking salt-induced and angiotensin II–induced hypertension to the failure to increase epoxygenase expression, particularly in the kidney.52–54

Genetic hypertension seems to be differentially linked to CYP expression and activity, because there seems to be no difference in the arachidonic acid–induced generation of EETs by kidneys from SHRs and Wistar-Kyoto rats.51 Such data imply that alternative mechanisms may underlie the increased renal vasodilator effect of arachidonic acid in the SHR kidney. One possibility is that hypertension is associated with alterations in the stability of EETs. This may well be the case, as a marked increase in the renal metabolism of EETs to dihydroxyeicosatrienoic acids has been reported during the development of hypertension in SHRs,47 suggesting that either the activity or the expression of the epoxide hydrolase is increased. Moreover, in SHRs17 and in rats55 and mice56 with angiotensin-II–induced hypertension, sEH inhibitors, which increase EET levels, markedly attenuate mean arterial blood pressure. Elevated EET levels also help to protect the kidney against hypertension-induced damage in different animal models.57,58

When searching for links between CYP expression and cardiovascular disease, it is perhaps more logical to look for changes in the production of a CYP-derived vasoconstrictor. 20-HETE is currently characterized as a prohypertensive eicosanoid, and has the potential to play a dual role in the regulation of blood pressure by virtue of its ability to induce contraction, as well as to inhibit sodium reabsorption (reviewed in Reference 59). The global consequences of enhanced renal 20-HETE production seem more closely related to prevention than aggravation of hypertension, as increased renal 20-HETE production after fibrate treatment has been linked to CYP ω-hydroxylase induction and attenuation of angiotensin II–induced,60 as well as desoxycorticosterone acetate salt–induced hypertension61 in mice. Also, inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats.62

That 20-HETE functionally antagonizes the actions of the EETs accounts for the finding that in the absence of cyclooxygenase inhibitors, bradykinin causes the release of a glomerular vasoconstrictor that antagonizes the vasodilator effect of EETs released from the efferent arteriole and perhaps from the glomerulus.63 Certainly, 20-HETE and EETs elicit opposite effects on the open probability of K+Ca channels,10,64 as well as on the Na-K-ATPase65 in vascular cells.

Several polymorphisms of the CYP enzymes expressed within endothelial cells exist. A polymorphism of the CYP 2J2 epoxygenase, which results in the attenuated binding of the transcription factor Sp1 and reduced promoter activity, has been associated with an enhanced risk of developing coronary artery disease in humans.66 However, there is also evidence indicating that a CYP 2C epoxygenase expressed in endothelial cells is able to generate superoxide anions in addition to EETs67 and that in patients with coronary artery disease the inhibition of CYP 2C–derived superoxide anion formation can markedly improve acetylcholine-induced vasodilatation in the forearm vasculature.68 Given this information, it is tempting to speculate that a decrease in CYP 2C activity within the vasculature can protect against the development of hypertension and its consequences. There is circumstantial evidence indicating that this may be the case, as a loss-of-function polymorphism of CYP 2C9 (CYP2C9*3), has been linked with a lower incidence of hypertension in a Chinese population.69 Other members of the CYP 2 family of enzymes may also participate in the regulation of blood pressure, and expression levels of CYP2E1 are reportedly lower in hypertensive SHRs than in normotensive Wistar rats.70

Acknowledgments

Work performed in our laboratory was supported by the Deutsche Forschungsgemeinschaft (SFB-TR 23, A6 to I.F. and FI 830/2-3 to R.B.).

  • Received December 14, 2005.
  • Revision received January 1, 2006.
  • Accepted January 27, 2006.

References

  1. ↵
    Fleming I. Cytochrome P450 epoxygenases as EDHF-synthase(s). Pharmacol Res. 2004; 49: 525–533.
    OpenUrlCrossRefPubMed
  2. ↵
    Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, Falck JR, Michelakis ED. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BKCa channels. Circulation. 2003; 107: 769–776.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol. 2001; 208: H2470–H2477.
    OpenUrl
  4. ↵
    Hillig T, Krustrup P, Fleming I, Osada T, Saltin B, Hellsten Y. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol (Lond). 2003; 546: 307–314.
    OpenUrlCrossRefPubMed
  5. ↵
    Matoba T, Shimokawa H, Kubota H, Morikawa K, Fujiki T, Kunihiro I, Mukai Y, Hirakawa Y, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun. 2002; 209: 909–913.
    OpenUrl
  6. ↵
    Büssemaker E, Popp R, Binder J, Busse R, Fleming I. Characterization of the endothelium-derived hyperpolarizing factor (EDHF) response in the human interlobar artery. Kidney Int. 2003; 63: 1749–1755.
    OpenUrlCrossRefPubMed
  7. ↵
    Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002; 23: 374–380.
    OpenUrlCrossRefPubMed
  8. ↵
    Coleman HA, Tare M, Parkington HC. Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease. Clin Exp Pharmacol Physiol. 2004; 31: 641–649.
    OpenUrlCrossRefPubMed
  9. ↵
    Shimokawa H, Matoba T. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pharmacol Res. 2004; 49: 543–549.
    OpenUrlCrossRefPubMed
  10. ↵
    Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996; 78: 415–423.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Zygmunt PM, Högestätt ED. Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br J Pharmacol. 1996; 117: 1600–1606.
    OpenUrlCrossRefPubMed
  12. ↵
    Gauthier KM, Liu C, Popovic A, Albarwani S, Rusch NJ. Freshly isolated bovine coronary endothelial cells do not express the BKCa channel gene. J Physiol. 2002; 545: 829–836.
    OpenUrlCrossRefPubMed
  13. ↵
    Huang A, Sun D, Jacobson A, Carroll MA, Falck JR, Kaley G. Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ Res. 2005; 96: 376–383.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Campbell WB, Falck JR, Gauthier K. Role of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor in bovine coronary arteries. Med Sci Monit. 2001; 7: 578–584.
    OpenUrlPubMed
  15. ↵
    Gauthier KM, Edwards EM, Falck JR, Reddy DS, Campbell WB. 14,15-Epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries. Hypertension. 2005; 45: 666–671.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Carroll MA, Balazy M, Margiotta P, Falck JR, McGiff JC. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J Biol Chem. 1993; 268: 12260–12266.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000; 87: 992–998.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Fang X, Weintraub NL, Oltman CL, Stoll LL, Kaduce TL, Harmon S, Dellsperger KC, Morisseau C, Hammock BD, Spector AA. Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide. Am J Physiol Heart Circ Physiol. 2002; 283: H2306–H2314.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Yang W, Gauthier KM, Reddy LM, Sangras B, Sharma KK, Nithipatikom K, Falck JR, Campbell WB. Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation. Hypertension. 2005; 45: 681–686.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKCa channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol. 2006; 290: H491–H499.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Batenburg WW, Garrelds IM, van Kats JP, Saxena PR, Danser AH. Mediators of bradykinin-induced vasorelaxation in human coronary microarteries. Hypertension. 2004; 43: 488–492.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Popp R, Bauersachs J, Hecker M, Fleming I, Busse R. A transferable, β-naphthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells. J Physiol (Lond). 1996; 497: 699–709.
    OpenUrlCrossRefPubMed
  23. ↵
    Li PL, Campbell WB. Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res. 1997; 80: 877–884.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Baron A, Frieden M, Bény J-L. Epoxyeicosatrienoic acids activate a high-conductance, Ca2+-dependent K+ channel on pig coronary artery endothelial cells. J Physiol (Lond). 1997; 504: 537–543.
    OpenUrlCrossRefPubMed
  25. ↵
    Imig JD, Inscho EW, Deichmann PC, Reddy KM, Falck JR. Afferent arteriolar vasodilation to the sulfonimide analog of 11,12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension. 1999; 33: 408–413.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Esguerra M, Wang J, Foster CD, Adelman JP, North RA, Levitan IB. Cloned Ca2+-dependent K+ channel modulated by a functionally associated protein kinase. Nature. 1994; 369: 563–565.
    OpenUrlCrossRefPubMed
  27. ↵
    Rueben A, Popp R, Busse R, Fleming I. Cytochrome P450 2c-derived epoxyeicosatrienoic acids (EETs) regulate Ca2+ signaling and hyperpolarization in endothelial cells (abstract). J Vasc Res. 2004; 41: 460.
    OpenUrlCrossRef
  28. ↵
    Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature. 2003; 424: 434–438.
    OpenUrlCrossRefPubMed
  29. ↵
    Vriens J, Owsianik G, Fisslthaler B, Suzuki M, Janssens A, Voets T, Morisseau C, Hammock BD, Fleming I, Busse R, Nilius B. Modulation of the Ca2+ permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res. 2005; 97: 908–915.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Earley S, Heppner TJ, Nelson MT, Brayden JE. TRPV4 forms a novel Ca2+ signaling complex with ryanodine receptors and BKCa channels. Circ Res. 2005; 97: 1270–1279.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Hoebel BG, Graier WF. 11,12-Epoxyeicosatrienoic acid stimulates tyrosine kinase activity in porcine aortic endothelial cells. Eur J Pharmacol. 1998; 346: 115–117.
    OpenUrlCrossRefPubMed
  32. ↵
    Fleming I, Fisslthaler B, Michaelis UR, Kiss L, Popp R, Busse R. The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers Arch. 2001; 442: 511–518.
    OpenUrlCrossRefPubMed
  33. ↵
    Potente M, Michaelis UR, Fisslthaler B, Busse R, Fleming I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem. 2002; 277: 15671–15676.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Munzenmaier DH, Harder DR. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol. 2000; 278: H1163–H1167.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Medhora M, Daniels J, Mundey K, Fisslthaler B, Busse R, Jacobs ER, Harder DR. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol. 2003; 284: H215–H224.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Michaelis UR, Falck JR, Schmidt R, Busse R, Fleming I. Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol. 2005; 25: 321–326.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci. 2005; 118: 5489–5498.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Chen J-K, Capdevila J, Harris RC. Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc Natl Acad Sci U S A. 2002; 99: 6029–6034.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, Busse R. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 2003; 17: 770–772.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Zhang B, Cao H, Rao GN. Fibroblast growth factor-2 is a downstream mediator of PI3K-AKT signaling in 14,15-epoxyericosatrienoic acid-induced angiogenesis. J Biol Chem. 2005; 281: 905–914.
    OpenUrlPubMed
  41. ↵
    Pozzi A, Macias-Perez I, Abair T, Wey S, Su Y, Zent R, Falk JR, Capdevila JH. Charaterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem. 2005; 280: 27138–27146.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, Zeldin DC. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther. 2005; 314: 522–532.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Potente M, Fisslthaler B, Busse R, Fleming I. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J Biol Chem. 2003; 278: 29619–29625.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, Kroetz DL. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol. 2000; 57: 1011–1020.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Frisbee JC, Falck JR, Lombard JH. Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. Am J Physiol Heart Circ Physiol. 2000; 278: H1517–H1526.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Kroetz DL, Huse LM, Thuresson A, Grillo MP. Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol Pharmacol. 1997; 52: 362–372.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Omata K, Abraham NG, Escalante B, Schwartzman ML. Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats. Am J Physiol. 1992; 262: F8–F16.
    OpenUrlPubMed
  48. ↵
    Pomposiello SI, Carroll MA, Falck JR, McGiff JC. Epoxyeicosatrienoic acid-mediated renal vasodilation to arachidonic acid is enhanced in SHR. Hypertension. 2001; 37: 887–893.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest. 1999; 104: 751–760.
    OpenUrlCrossRefPubMed
  50. ↵
    Pfister SL, Falck JR, Campbell WB. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am J Physiol. 1991; 261: H843–H852.
    OpenUrlPubMed
  51. ↵
    Pomposiello SI, Quilley J, Carroll MA, Falck JR, McGiff JC. 5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. Hypertension. 2003; 42: 548–554.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension. 2003; 42: 775–780.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Kaergel E, Muller DN, Honeck H, Theuer J, Shagdarsuren E, Mullally A, Luft FC, Schunck WH. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension. 2002; 40: 273–279.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Sarkis A, Lopez B, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens. 2004; 13: 205–214.
    OpenUrlCrossRefPubMed
  55. ↵
    Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002; 39: 690–694.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension. 2005; 45: 759–765.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004; 15: 1244–1253.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005; 46: 975–981.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002; 82: 131–185.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension. 2005; 45: 730–735.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Honeck H, Gross V, Erdmann B, Kargel E, Neunaber R, Milia AF, Schneider W, Luft FC, Schunck WH. Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice. Hypertension. 2000; 36: 610–616.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    Hoagland KM, Flasch AK, Roman RJ. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension. 2003; 42: 669–673.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Wang H, Garvin JL, Falck JR, Ren Y, Sankey SS, Carretero OA. Glomerular cytochrome P-450 and cyclooxygenase metabolites regulate efferent arteriole resistance. Hypertension. 2005; 46: 1175–1179.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Harder DR, Lange AR, Gebremedhin D, Birks EK, Roman RJ. Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. J Vasc Res. 1997; 34: 237–243.
    OpenUrlCrossRefPubMed
  65. ↵
    Randriamboavonjy V, Kiss L, Falck JF, Busse R, Fleming I. The synthesis of 20-HETE in small porcine coronary arteries antagonizes EDHF-mediated relaxation. Cardiovasc Res. 2005; 65: 487–494.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, Huesing A, Maisch B, Zeldin DC, Liao JK. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004; 110: 2132–2136.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    Fleming I, Michaelis UR, Bredenkötter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res. 2001; 88: 44–51.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation. 2004; 109: 178–183.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, Mo W, Zhou HH. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta. 2004; 348: 57–61.
    OpenUrlCrossRefPubMed
  70. ↵
    Zhang F, Deng H, Kemp R, Singh H, Gopal VR, Falck JR, Laniado-Schwartzman M, Nasjletti A. Decreased levels of cytochrome P450 2E1-derived eicosanoids sensitize renal arteries to constrictor agonists in spontaneously hypertensive rats. Hypertension. 2005; 45: 103–108.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
April 2006, Volume 47, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • EETs and Endothelium-Derived Hyperpolarizing Factor
    • More Than Regulators of Vascular Tone?
    • EETs and Hypertension
    • Acknowledgments
    • References
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function
    Ingrid Fleming and Rudi Busse
    Hypertension. 2006;47:629-633, originally published March 23, 2006
    https://doi.org/10.1161/01.HYP.0000208597.87957.89

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function
    Ingrid Fleming and Rudi Busse
    Hypertension. 2006;47:629-633, originally published March 23, 2006
    https://doi.org/10.1161/01.HYP.0000208597.87957.89
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Vascular Disease
    • Peripheral Vascular Disease
  • Basic, Translational, and Clinical Research
    • Vascular Biology
    • Angiogenesis

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured